Mode
Text Size
Log in / Sign up

Allergy & Immunology

345 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patients
Allergy & Immunology Phase II
VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patients Can a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?
The VALIANT study, a phase 2 trial, evaluated the efficacy and safety of subcutaneous verekitug (UPB-101) versus placebo in adults with seve…
A new asthma injection aims to reduce dangerous flare-ups and improve breathing for adults with severe asthma in a completed trial.
Pink vs. white inhaler actuators studied for asthma symptom perception in crossover trial
Allergy & Immunology Phase III
Pink vs. white inhaler actuators studied for asthma symptom perception in crossover trial Study compares pink and white asthma inhalers for how patients perceive symptoms
A phase IIIb randomized, double-blind, crossover trial in 78 adults with moderate to severe asthma compared identical beclomethasone/formote…
Asthma patients tried identical inhalers in pink or white to see if color changed how they perceived their symptoms and which device they pr…
Digital albuterol system feasibility studied in 333 asthma patients with suboptimal control
Allergy & Immunology Phase IV
Digital albuterol system feasibility studied in 333 asthma patients with suboptimal control Can a smart inhaler help people with uncontrolled asthma breathe easier?
A phase 4, open-label, multicenter feasibility study randomized 333 participants aged 13+ with suboptimal asthma control to either the Albut…
A new smart inhaler system tested for 12 weeks to see if it helps people with uncontrolled asthma breathe easier, but results are not yet av…
Phase 4 trial compares LPV/r plus raltegravir versus LPV/r plus N(t)RTIs for HIV after first-line failure
Allergy & Immunology Phase IV
Phase 4 trial compares LPV/r plus raltegravir versus LPV/r plus N(t)RTIs for HIV after first-line failure Study compares two HIV treatment strategies after first-line therapy fails
A phase 4 randomized controlled trial enrolled 558 HIV-infected subjects who had virologically failed first-line NNRTI-based therapy. The st…
A completed Phase 4 trial compared two HIV treatment strategies after first-line therapy fails, but results for viral suppression and safety…
Phase 2 trial tests amlitelimab add-on therapy in adults with moderate-to-severe asthma
Allergy & Immunology Phase II
Phase 2 trial tests amlitelimab add-on therapy in adults with moderate-to-severe asthma Phase 2 trial tests new asthma drug amlitelimab in adults with moderate-to-severe asthma
A phase 2 randomized controlled trial enrolled 437 adults with moderate-to-severe asthma globally to evaluate amlitelimab versus placebo. No…
A new asthma drug called amlitelimab is being tested to see if adding it to current treatments can reduce severe asthma attacks in adults wi…
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma
Allergy & Immunology Phase II
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma Could a new drug help people with severe asthma breathe easier?
A Phase 2 trial is assessing the safety and efficacy of brenipatide versus placebo in 531 participants with moderate-to-severe asthma. The p…
A new asthma drug trial aims to reduce flare-ups and improve breathing for adults with moderate-to-severe asthma over the next year.
Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma
Allergy & Immunology Phase II
Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma Can KT-621 help people with severe asthma breathe easier?
A Phase 2b trial is assessing KT-621's efficacy and safety in 264 adults with moderate to severe eosinophilic asthma.
A new drug called KT-621 is being tested to help people with uncontrolled moderate to severe eosinophilic asthma breathe easier by improving…
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer
Allergy & Immunology Phase II
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer Can New Treatments Help Fight HIV-Related Anal Cancer More Effectively?
This Phase II trial investigates the safety of reduced intensity CRT in low-risk HIV-associated anal cancer and nivolumab post-CRT in high-r…
A new trial tests gentler radiation and chemotherapy for low-risk HIV anal cancer, while adding immunotherapy for high-risk cases to improve…
IMP2ART Pilot Shows Feasibility for Asthma Self-Management in UK Primary Care
Allergy & Immunology RCT
IMP2ART Pilot Shows Feasibility for Asthma Self-Management in UK Primary Care Could Better Asthma Management Save You from Unnecessary Doctor Visits?
The IMP2ART pilot cRCT demonstrated feasibility and acceptability of an asthma self-management strategy in UK primary care, with successful …
A new UK strategy helps asthma patients breathe easier and avoid emergency room visits through personalized action plans and regular profess…